NCT04367675Active, not recruitingPhase 1
Phase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 Mutations
Abramson Cancer Center at Penn Medicine1 site in 1 country44 target enrollmentStarted: April 20, 2021Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 44
- Locations
- 1
- Primary Endpoint
- Dose Limiting Toxicities
Study Overview
Brief Summary
The research study is being conducted to test an experimental vaccine to potentially prevent cancer for people with BRCA1 or BRCA2 mutations. This study will test if the vaccine is safe (without significant side effects) and test a new way of administering vaccines. It will also test whether the vaccine activates your immune system.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Cohort A Inclusion Criteria:
- •Signed and dated IRB approved informed consent.
- •Females and males age 18+.
- •Documented carrier of a pathogenic or likely pathogenic mutation in BRCA1 or BRCA
- •Diagnosis of invasive breast cancer, invasive ovarian cancer, pancreatic cancer (apart from neuroendocrine) or prostate cancer with completion of adjuvant therapy and no clinical evidence of disease according to standard of care.
- •Minimum of 2 clear sites on the skin to allow for injection.
- •ECOG performance status of
- •Normal ECG or ECG without clinically significant findings and which does not require clinical action.
- •Normal bone marrow, hepatic, and renal function.
- •Females who are post-menopausal only.
- •Male subjects with reproductive potential must be willing to use a condom with female partners of reproductive potential and their female sexual partners should use an additional highly effective method of birth control. This is required from screening through 24 weeks after the last dose of immunotherapy.
- •Able and willing to comply with all study procedures.
- •Cohort B Inclusion Criteria
- •Signed and dated IRB approved informed consent.
- •Females and males age 18+.
- •Documented carrier of a pathogenic or likely pathogenic mutation in BRCA1 or BRCA
- •With or without prior prophylactic (but not therapeutic) mastectomy or salpingo-oophorectomy.
- •Minimum of 2 clear sites on the skin to allow for injection.
- •ECOG performance status of
- •Normal ECG or ECG without clinically significant findings and which does not require clinical action.
- •Normal bone marrow, hepatic, and renal function.
- •Females who are post-menopausal only.
- •Male subjects with reproductive potential must be willing to use a condom with female partners of reproductive potential and their female sexual partners should use an additional highly effective method of birth control. This is required from screening through 24 weeks after the last dose of immunotherapy.
- •Able and willing to comply with all study procedures.
Exclusion Criteria
- •Previous treatment with INO-5401 or IL-12 containing therapy, or any other DNA immunotherapy.
- •Prior history of invasive cancer other than those listed above. History of localized superficial non-melanoma skin cancers, melanoma in situ, cervical intraepithelial neoplasia, or breast ductal carcinoma in situ is allowed.
- •Pregnant or breast-feeding subjects.
- •Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation; continued participation in an observational study is allowed.
- •Cardiac pre-excitation syndromes.
- •Prior major surgery within 4 weeks of first study treatment.
- •Presence of acute or chronic bleeding or clotting disorder that would contraindicate intramuscular injections or use of blood thinners within 2 weeks of first study treatment.
- •Any concurrent condition requiring the continued or anticipated use of systemic steroids or immunosuppressive therapy. All systemic corticosteroids must be discontinued at least 4 weeks prior to first study treatment.
- •History of clinically significant disease or other immunosuppressive disease.
- •HIV infection.
- •Known history of hepatitis B and/or hepatitis C with active viral replication.
- •Receipt of any blood product within 2 weeks before signing ICF.
- •Administration of any vaccine, except influenza vaccine, within 4 weeks of the first study treatment. Administration of influenza vaccine within 2 weeks of first study treatment.
- •Presence of metal implants or implantable medical device within 5 cm of the planned site of injection/EP including a cardioverter-defibrillator (ICD) or pacemaker (to prevent a life-threatening arrhythmia) that is located ipsilateral to the intended deltoid injection site, unless deemed acceptable by a cardiologist.
- •Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
- •Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint.
- •Any other conditions judged by the investigator that would limit the evaluation of the subject.
- •Cohort B Exclusion Criteria
- •Previous treatment with INO-5401 or IL-12 containing therapy, or any other DNA immunotherapy.
- •Prior history of invasive cancer other than those listed above. History of localized superficial non-melanoma skin cancers, melanoma in situ, cervical intraepithelial neoplasia, or breast ductal carcinoma in situ is allowed.
- •Pregnant or breast-feeding subjects.
- •Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation; continued participation in an observational study is allowed.
- •Cardiac pre-excitation syndromes.
- •Prior major surgery within 4 weeks of first study treatment.
- •Presence of acute or chronic bleeding or clotting disorder that would contraindicate intramuscular injections or use of blood thinners within 2 weeks of first study treatment.
- •Any concurrent condition requiring the continued or anticipated use of systemic steroids or immunosuppressive therapy. All systemic corticosteroids must be discontinued at least 4 weeks prior to first study treatment.
- •History of clinically significant disease or other immunosuppressive disease.
- •HIV infection.
- •Known history of hepatitis B and/or hepatitis C with active viral replication.
- •Receipt of any blood product within 2 weeks before signing ICF.
- •Administration of any vaccine, except influenza vaccine, within 4 weeks of the first study treatment. Administration of influenza vaccine within 2 weeks of first study treatment.
- •Presence of metal implants or implantable medical device within 5 cm of the planned site of injection/EP including a cardioverter-defibrillator (ICD) or pacemaker (to prevent a life-threatening arrhythmia) that is located ipsilateral to the intended deltoid injection site, unless deemed acceptable by a cardiologist.
- •Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
- •Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint.
- •Any other conditions judged by the investigator that would limit the evaluation of the subject.
Arms & Interventions
INO-5401
Experimental
Participants receive INO-5401 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
Intervention: INO-5401 (Drug)
INO-5401 and INO-9012
Experimental
Participants receive INO-5401 and INO-09012 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
Intervention: INO-9012 (Drug)
INO-5401
Experimental
Participants receive INO-5401 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
Intervention: Cellectra 2000 (Device)
INO-5401 and INO-9012
Experimental
Participants receive INO-5401 and INO-09012 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
Intervention: INO-5401 (Drug)
INO-5401 and INO-9012
Experimental
Participants receive INO-5401 and INO-09012 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
Intervention: Cellectra 2000 (Device)
Outcomes
Primary Outcomes
Dose Limiting Toxicities
Time Frame: for 2 years after last dose of study treatment
Dose-limiting toxicities will be classified by system organ class (SOC), preferred term (PT), severity, and relationship to Study Treatment.
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in RemissionNo Evidence of DiseaseHER2/Neu NegativeStage IB Breast CancerStage III Breast CancerStage IIIA Breast CancerStage IIA Breast CancerStage II Breast CancerStage IIIB Breast CancerOne or More Positive Axillary NodesStage IIIC Breast CancerStage IIB Breast CancerNCT02780401University of Washington24
Completed
Phase 1
The phase I,II clinical study of cancer vaccine for intractable malignant tumor expressing MAGE-A4-antigeIntractable malignant tumors expressing MAGE-A4 antigenJPRN-UMIN000001999Department of Surgical Oncology, Hokkaido University Graduate School of Medicine18
Completed
Not Applicable
A phase I clinical trial of cancer vaccine using multiple antigen epitope peptides for advanced cervical canceradvanced and recurrent cervical cancerJPRN-UMIN000003999Saitama medical university international medical center18
Completed
Phase 1
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV CancerSolid Tumors Stage II, Stage III and Stage IVBreast CancerProstate CancerColorectal CancerOvarian CancerMelanomaNon-small Cell Lung CancerSarcomaNCT01065441Michael Har-Noy9
Completed
Phase 1
Phase I clinical study of tumor-specific vaccine using novel tumor antigen SCRN1-derived HLA*0201 restricted epitope peptide against advanced gastric cancerAdvanced gastric cancerJPRN-UMIN000001013Institute of Medical Science, University of Tokyo6